Drug intelligence / Profile preview

Clade B Recombinant, Oligomeric gp140 + MF59

Development stage: Phase 1
Lead developer: Novartis
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A vaccine formulation combining recombinant HIV envelope glycoprotein (gp140) from Clade B with the MF59 adjuvant. MF59 is an oil-in-water emulsion composed of squalene that enhances immune responses to vaccine antigens by creating a transient immunocompetent environment at the injection site and recruiting immune cells.

Targets

gp140 (HIV-1 gp140)

Beyond the preview

Go deeper on Clade B Recombinant, Oligomeric gp140 + MF59.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clade B Recombinant, Oligomeric gp140 + MF59.

Explore the full profile